Live Breaking News & Updates on Sunlight Trial

Stay updated with breaking news from Sunlight trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer. ....

Adverse Event Management , Colorectal Cancer , Optimizing Treatment Approaches , Refractory Metastatic , Colorectal Cancer Treatment , Mcrc Treatment , Fresco 2 , Refractory Colorectal Cancer , Refractory Crc , Tas 102 , Safety Profile , Sunlight Trial ,

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats. ....

France General , United States , Julien Taieb , Gastrointestinal Oncology Department , Georges Pompidou European Hospital , Université De Paris , Fda Approval Of Trifluridine Tipiracil Plus Bevacizumab , Patients With Pretreated Metastatic Colorectal Cancer , Sunlight Trial ,

TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm. ....

United States , France General , Thierry Conroy , Pierre Fabre , Deborah Schrag , Drug Administration , Taiho Oncology Inc , Gastrointestinal Oncology Department , Merck Kgaa , Merck Kga , Georges Pompidou European Hospital , New England Journal , Taiho Oncology , Patients With Metastatic Colorectal Cancer , Third Line Treatment With Trifluridine Tipiracil Plus Bevacizumab , Sunlight Trial , Tas 102 Plus Bevacizumab , Julien Taieb , Georges Pompidou European Hospital At Université De Paris ,

FDA Grants Priority Review to TAS-102 Plus Bevacizumab for Refractory mCRC

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer. ....

United States , European Union , North America , Cancers Symposium , Priority Review , Trifluridine Tipiracil , Tas 102 , Tas 102 Plus Bevacizumab , Colorectal Cancer , Sunlight Trial , Asco Gi , Gastrointestinal Cancers Symposium , Gastrointestinal Cancer , Supplemental New Drug Application ,

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials. ....

Metastatic Colorectal Cancer With , Positive Disease , Combination Strategies , Colorectal Cancer , Metastatic Crc , Immune Checkpoint Inhibitors , Tki Therapy , Tyrosine Kinase Inhibitors , Stellar 303 , Sunlight Trial , Combination Therapy ,